Results 191 to 200 of about 114,445 (279)
Personalized Surgery for Allergic Fungal Rhinosinusitis
ABSTRACT Background Allergic fungal rhinosinusitis (AFRS) frequently presents as unilateral or asymmetric disease. In cases with minimal disease on one side, the question remains as to the necessary extent of surgery. Objective To determine the relationship between symmetry and clinical characteristics in AFRS patients, with a focus on implications for
Erin E. Briggs +7 more
wiley +1 more source
Prognostic Significance of the Ki-67 Index with an Optimal Cut-off Value of 32.5% in Uterine Sarcoma and Uterine Carcinosarcoma: A Retrospective Cohort Study. [PDF]
Ye P, Wang F, Dai X, Hu X, Wang Y.
europepmc +1 more source
ABSTRACT Objective To compare the ability of large language models (LLMs) and otolaryngologists to identify prognostic signals from brief clinical vignettes in CRSwNP. Methods In this blinded study, 68 adults initiating biologic therapy for CRSwNP (≥ 36 months follow‐up) were represented by standardized vignettes derived from documentation immediately ...
Sholem Hack +12 more
wiley +1 more source
Doxycycline for epistaxis in hereditary hemorrhagic telangiectasia: genotype-stratified outcomes. [PDF]
Santiago-Beniquez J +11 more
europepmc +1 more source
ABSTRACT Objective To evaluate and compare the performance of ChatGPT‐5.5 (2026) and DeepSeek‐V3 (2026) in classifying CRS resectability according to the EPOS 2020 guidelines, employing various prompting strategies. Methods In this retrospective study, 150 chronic rhinosinusitis cases were reviewed, and three rhinology experts classified resectability ...
Jia‐Hong Lao +8 more
wiley +1 more source
Sleepiness and attention in sleep-clinic patients and their associations with apnea severity and treatment. [PDF]
Schwab A +4 more
europepmc +1 more source
ABSTRACT Background Biologic therapies are effective for severe, uncontrolled CRSwNP, yet real‐world data on treatment persistence remain limited. Methods This retrospective single‐center study included 95 adults with CRSwNP who initiated dupilumab (88.4%), mepolizumab, or omalizumab between 2021 and 2025.
Hen Chaushu +8 more
wiley +1 more source
Trade-offs and synergies of ecosystem services in the yellow river basin: spatial dynamics and driving factors. [PDF]
Ma W, Zhao Z, Zhang J, Xun M.
europepmc +1 more source

